Validity of indirect comparisons in meta-analysis

Lancet

Volumn 369, Issue 9558, 2007, Pages 270-

  Caldwell, Deborah M ^a   Gibb, DM ^b   Ades, AE ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DELAVIRDINE; EFAVIRENZ; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; DELVARIDINE; ORGANIC COMPOUND; UNCLASSIFIED DRUG;

DRUG POTENCY; HUMAN; LETTER; PRIORITY JOURNAL; VALIDITY; CLINICAL TRIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; META ANALYSIS; METHODOLOGY; NOTE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS; HUMANS; META-ANALYSIS; ORGANIC CHEMICALS;

EID: 33846399997     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60138-X     Document Type: Letter

References (3)

1. Chou R., Rongwei F., Hoyt Huffman L., and Korthuis P. Initial highly-active antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. Lancet 368 (2006) 1503-1515
2. Huque M. Experiences with meta-analysis in NDA submissions. Prof Biopharmac Sec Am Stat Assoc 2 (1988) 33
3. Caldwell D., Ades A., and Higgins J. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331 (2005) 897-900